for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-Curevac NV Says Initiates Phase 2A Clinical Trial Of COVID-19 Vaccine Candidate

Sept 29 (Reuters) - CureVac NV:

* PHASE 2A CLINICAL TRIAL OF COVID-19 VACCINE CANDIDATE

* STUDY CONDUCTED IN PERU AND PANAMA

* FIRST PARTICIPANT HAS BEEN DOSED IN A PHASE 2A CLINICAL TRIAL OF ITS COVID-19 VACCINE CANDIDATE, CVNCOV

* PARTICIPANTS WILL RECEIVE TWO VACCINATIONS AT INTERVALS OF 28 DAYS

* PHASE 2A IN OLDER ADULTS ARE EXPECTED LATER IN Q4 2020

* CUREVAC PLANS TO INITIATE GLOBAL PHASE 2B/3 CLINICAL TRIAL ENROLLING APPROXIMATELY 30,000 PARTICIPANTS IN Q4 OF 2020

* CUREVAC PLANS TO INITIATE GLOBAL PHASE 2B/3 CLINICAL TRIAL ENROLLING APPROXIMATELY 30,000 PARTICIPANTS IN Q4 OF 2020

* TRIAL INVOLVES 690 PARTICIPANTS, INCLUDING OLDER ADULTS Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up